Oncodesign, Sanofi ink research collaboration and license agreement

Friday, September 14, 2012 11:57 AM

Oncodesign, a French drug discovery company and oncology pharmacology service provider, has entered into a strategic research collaboration with global healthcare company Sanofi to apply Oncodesign's Nanocyclix technology to Sanofi kinase target programs.

Oncodesign will exclusively apply its Nanocyclix technology platform in multiple undisclosed Sanofi kinase programs for a number of therapeutic applications over a period of four years. Oncodesign is entitled to a technology access fee and discovery, development, regulatory and commercial milestone payments totaling up to $170 million and low single digit royalties on net sales.

The application of Nanocyclix to Sanofi's kinase lead programs aims to allow for a quicker selection of development candidates for multiple undisclosed kinase targets in kinase families that are notoriously difficult to address.

Nanocyclix is a proprietary medicinal chemistry technology and research platform based on macrocyclisation chemical methodology and knowledge that gives access to potent and selective kinase inhibitors based on shape complementarity in the ATP binding site of kinases. In this way, unprecedented selectivity is achieved even among kinases with high homology. In addition, the technology allows rapid improvement in the pharmacokinetic properties of the Nanocyclix leads based on established knowledge.

"This new agreement illustrates the leading position of Oncodesign in the kinase inhibitor field. Our Nanocyclix technology is now clearly established as a high value, differentiating approach that gives access to next generation kinase inhibitors in multiple therapeutic indications," said Jan Hoflack, Ph.D., CSO of Oncodesign.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs